17 results
The main objectives of the trial are to demonstrate the effectiveness of BI 685509 and to characterize the dose-response relationship for BI 685509 in patients with DKD by assessing 3 doses and placebo.
The main objective of the study is to assess the albuminuria lowering effects of semaglutide 2.4 mg s.c. once weekly (Semaglutide 3 mg/ml) compared to placebo in obese/overweight non-diabetic individuals with elevated albuminuria.
Primary Objective: To test clinical safety of PNMP up to 6 hours as a modality to assess viability and evaluate initiation of tissue repair ex-situ in donor kidneys prior to transplantation.Secondary Objective(s): To monitor standard and novel renal…
This study has been transitioned to CTIS with ID 2024-514130-20-00 check the CTIS register for the current data. The primary objective of this study is to assess the efficacy of twice-weekly SC doses of pegcetacoplan compared with that of placebo in…
This study has been transitioned to CTIS with ID 2023-509331-83-00 check the CTIS register for the current data. Primary objective adults:To demonstrate the superiority of iptacopan (200 mg b.i.d.) compared to placebo in reducing proteinuria at 6…
Primary Objective is to test the feasibility of a strategy in which patient preference, after a short exposure to treatment options, determines the choice for a specific phosphate binder and whether this strategy will improve patient*s satisfaction.…
Objectives: 1. To what extent does the CVRM risk profile and co-morbid conditions differ between individuals with (UCC-SMART) and without (UHP-UCC) symptoms of heart failure, but with similar levels of echocardiographic structural- and functional…
To evaluate the prevalence of C-TMA in patients presenting with TMA, either with coexisting conditions or not. Furthermore, (i) the diagnostic performance of an in-house developed ex vivo test, (ii) dynamics of complement measures during follow-up,…
This study has been transitioned to CTIS with ID 2023-504884-17-00 check the CTIS register for the current data. The main goal of this study is to find out whether finerenone in combination with either an ACE inhibitor or an ARB can reduce the…
This study has been transitioned to CTIS with ID 2023-507977-16-00 check the CTIS register for the current data. To evaluate the efficacy of ravulizumab compared with placebo to reduceproteinuria in adult participants with LN or IgAN.
Primary objectives:To perform a study to:1. Estimate the prevalence of elevated albuminuria in subjects with a high risk of chronic kidney disease in the Netherlands.2. Evaluate which screening approach would be most effective based on costs per…
Main objectives: 1 Perform regression and correlation analysis on urea concentrations in sweat/saliva versus blood at the start of hemodialysis (C0), at the end of hemodialysis (Ct) and on the ratio (Ct/C0). 2 Feasibility of sweat and/or saliva…
This study investigates how well the combination of the two drugs, zibotentan and dapagliflozin, works for the treatment of chronic kidney disease in patients. We compare the effect of zibotentan and dapagliflozin with the effect of a placebo. The…
The aim of this pilot study is to further unravel the pathophysiologic mechanism of NS-induced hypercholesterolemia which willfurther guide the treatment of patients with NS.Given the recent insights on PCSK9-ENaC inhibition, our hypothesis is that…
To assess the albuminuria lowering effects of dapagliflozin in subjects with and without diabetes or hypertension and persistent elevated albuminuria.
We want to map the entire bacterial ecosystem in the gastrointestinal tract of patients with IgA nephropathy, in order to gain insight into the processes that may play a role in the development of the disease. This can then lay the foundation for…
This study has been transitioned to CTIS with ID 2023-508690-92-00 check the CTIS register for the current data. The primary objective is to evaluate the long-term safety and tolerability of iptacopan in eligible participants. The primary clinical…